News
-
An effort to return remaining units of Primatene Mist epinephrine inhalers to the market failed in the US House of Representatives on December 12, 2012 by a vote of 229-182. Primatene Mist, a CFC-propelled MDI… Read more . . .
-
RDD Online and Aptar Pharma have announced that registration for RDD Europe 2013 is now open. The meeting will take place at the Intercontinental Hotel in Berlin, Germany, May 21-24, 2013, with more than 450… Read more . . .
-
Theravance has begun a dose ranging Phase 2b study of its TD-4208 inhalation solution in approximately 60 patients with moderate to severe COPD. According to the company, “The goal of Theravance’s LAMA program for respiratory… Read more . . .
-
Aptar Pharma has “significantly increased” the production capacity at its facility in Eigeltingen, Germany for nasal delivery pumps for preservative free formulations, the company says, in order to meet continuously rising demand for preservative free… Read more . . .
-
Aradigm Corporation has agreed to sell 50 million shares of common stock at $0.12 per share to two existing shareholders, generating net proceeds of approximately $5.6 million after fees and expenses. According to Aradigm President… Read more . . .
-
Device company Clement Clarke International has launched the Flo-Tone MDI trainer, a device that connects to the mouthpiece of a metered dose inhaler to assist patients and healthcare providers in learning proper inhalation technique. The… Read more . . .
-
Almirall’s Tudorza Pressair aclidinium bromide dry powder inhaler for the maintenance treatment of COPD is now available in the United States, where it is being marketed by Forest Laboratories. The twice-daily anticholinergic was approved in… Read more . . .
-
DDL 23 concluded on Friday, December 7 with a final plenary talk and podium session, the announcement of contest winners, and news about next year’s DDL meeting. . . . Read more Read more . . .
-
The second day of DDL 23 got underway with an invited talk from OINDP consultant Steve Nichols, who reviewed the state of the inhaled drug market in 2012 with a promise to answer the question,… Read more . . .
-
Meeting chair Gary Pitcairn started off DDL 23 with the announcement of some attendance statistics: just under 500 attendees have registered for this year’s meeting, with 35% of them from pharma companies, 17% from academia,… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.